Matches in Wikidata for { <http://www.wikidata.org/entity/Q66344284> ?p ?o ?g. }
Showing items 1 to 41 of
41
with 100 items per page.
- Q66344284 description "assaig clínic" @default.
- Q66344284 description "clinical trial" @default.
- Q66344284 description "clinical trial" @default.
- Q66344284 description "clinical trial" @default.
- Q66344284 description "clinical trial" @default.
- Q66344284 description "ensaio clínico" @default.
- Q66344284 description "ensayo clínico" @default.
- Q66344284 description "ensayu clínicu" @default.
- Q66344284 description "essai clinique" @default.
- Q66344284 description "klinisch onderzoek" @default.
- Q66344284 description "клінічне випробування" @default.
- Q66344284 description "կլինիկական փորձարկում" @default.
- Q66344284 name "A Phase III Clinical Trial to Evaluate Patient´s Preference of Subcutaneous Trastuzumab (SC) Versus Intravenous (IV) Administration in Patients With HER2 Positive Advanced Breast Cancer (ABC)." @default.
- Q66344284 name "A Phase III Clinical Trial to Evaluate Patient´s Preference of Subcutaneous Trastuzumab" @default.
- Q66344284 type Item @default.
- Q66344284 label "A Phase III Clinical Trial to Evaluate Patient´s Preference of Subcutaneous Trastuzumab (SC) Versus Intravenous (IV) Administration in Patients With HER2 Positive Advanced Breast Cancer (ABC)." @default.
- Q66344284 label "A Phase III Clinical Trial to Evaluate Patient´s Preference of Subcutaneous Trastuzumab" @default.
- Q66344284 prefLabel "A Phase III Clinical Trial to Evaluate Patient´s Preference of Subcutaneous Trastuzumab (SC) Versus Intravenous (IV) Administration in Patients With HER2 Positive Advanced Breast Cancer (ABC)." @default.
- Q66344284 prefLabel "A Phase III Clinical Trial to Evaluate Patient´s Preference of Subcutaneous Trastuzumab" @default.
- Q66344284 P1132 Q66344284-ADB87096-37CF-4BB5-8B06-7B6A5FA6E552 @default.
- Q66344284 P1476 Q66344284-F07ACD9C-B4DA-4E35-BCD4-EF81AB96BB67 @default.
- Q66344284 P17 Q66344284-BC183CA8-0DDA-4011-8147-97A8D3B4D2C7 @default.
- Q66344284 P1813 Q66344284-AA2561FB-BA10-4A5E-8554-84935ADF1803 @default.
- Q66344284 P2899 Q66344284-119F0E10-64B6-4AF7-9B83-83BE572FB848 @default.
- Q66344284 P3098 Q66344284-1D76D53C-FA81-49F0-B2D4-0137ED9756B7 @default.
- Q66344284 P31 Q66344284-EDEF028D-B743-41EF-AC66-EEE394677E24 @default.
- Q66344284 P580 Q66344284-185C1DF7-CCDD-4855-9CC0-2E6D83348B93 @default.
- Q66344284 P582 Q66344284-58B7F81D-151D-4C4C-8AF4-BEE646E5626D @default.
- Q66344284 P6099 Q66344284-3A30C653-8881-47CF-8511-5F5BAB359F79 @default.
- Q66344284 P8363 Q66344284-28A4D0EC-B26E-4BA3-B599-7621C617C347 @default.
- Q66344284 P1132 "+160" @default.
- Q66344284 P1476 "Clinical Trial to Evaluate Patient´s Preference of Subcutaneous Trastuzumab (SC) Versus Intravenous (IV) Administration in Patients With HER2 Positive Advanced Breast Cancer (ABC) Who Have Received Intravenous Trastuzumab at Least 4 Months and Without Disease Progression" @default.
- Q66344284 P17 Q29 @default.
- Q66344284 P1813 "ChangHER-SC" @default.
- Q66344284 P2899 "+18" @default.
- Q66344284 P3098 "NCT01875367" @default.
- Q66344284 P31 Q30612 @default.
- Q66344284 P580 "2013-09-01T00:00:00Z" @default.
- Q66344284 P582 "2018-07-01T00:00:00Z" @default.
- Q66344284 P6099 Q42824827 @default.
- Q66344284 P8363 Q78089383 @default.